OM1 to Present Groundbreaking Research on GLP-1 Agonists and Suicidal Ideation at ISPOR 2025
What:
OM1, the leader in real-world data and AI-driven insights in mental health for life sciences, announced an upcoming poster presentation hosted by Jessica Probst, OM1's Principal, Real World Evidence. The poster focuses on the linkage between Glucagon-like Peptide 1 Receptor Agonists (GLP-1s) and Suicidal Ideation (SI). Consistent with other findings and despite warnings on the label, there was no significant increase in SI prevalence after GLP-1 initiation.
When:
The poster session will be held at ISPOR 2025 on Wednesday, May 14, from 4:00 – 7:00 PM, with a discussion period from 6:00 – 7:00 PM.
Key Findings:
Amid growing scrutiny of GLP-1 receptor agonists (used in diabetes and obesity), OM1's real-world study finds no significant change in suicidal ideation (SI) following treatment initiation across both therapeutic populations.
Why It Matters:
GLP-1s indicated for obesity feature a package label warning for suicidal ideation, whereas those indicated for diabetes do not. This research adds to the growing body of evidence exploring whether this warning may present an unnecessary obstacle to treatment and a potential barrier to equitable access to healthcare for a long stigmatized population.
Suicidal ideation is often undercoded or missing entirely in claims-based datasets. By applying natural language processing (NLP) to unstructured clinician notes, OM1's study captures a richer, more nuanced view of patient mental health. This study reinforces the role of AI and real-world data (RWD) in advancing pharmacovigilance and public health safety.
Implications for Stakeholders:
Supports regulatory and labeling evaluations,
Facilitates risk-benefit communications,
Enables signal detection and mitigation strategies.
About OM1:
OM1 is pioneering cutting-edge healthcare innovation through its insights-driven technology and data. It specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWE.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
17 minutes ago
- Business Wire
Connexall Now Available in Epic Toolbox as Alert Manager Solution
TORONTO--(BUSINESS WIRE)--Connexall, a global leader in clinical communication, alarm management, and workflow optimization, today announced its designation in the 'Alert Manager Integration' category in Epic Toolbox on Showroom. This achievement highlights Connexall's expertise in driving seamless integration with disparate systems to provide intelligently routed clinical and operational alerts directly into Epic – including Rover, Haiku, and Canto. Connexall collaborated with Epic to provide input into the design of the Alert Manager Integration blueprint, which defines Epic's recommended practices for products in this category. Within Showroom, Toolbox is a designation for products that use established integration technology in select categories to meet Epic defined recommended connection practices for that area. The eligible categories focus on the most impactful and innovative areas for Epic customers. Connexall's integration platform provides deep interoperability and proven outcomes for health systems looking to streamline alert management and reduce alarm fatigue. 'This recognition by Epic demonstrates Connexall's commitment to improving clinical workflows, patient safety, and staff and clinician satisfaction for over 25 years,' said Connexall CEO Sandy Saggar. 'We are honored to support the standard in the Alert Manager Integration category in the Epic Toolbox.' With its extensive integration library, Connexall offers bi-directional integration with Epic and consolidates alerts from various systems—such as nurse call, patient monitoring, IV pumps, RTLS, and smart beds—ensuring the right information reaches the right care team member, on the right device, at the right time. This milestone reaffirms Connexall's role in the healthcare ecosystem—alleviating burden, increasing efficiency, and improving patient care. About Connexall Connexall is a connected care and interoperability platform, seamlessly integrating disparate healthcare technologies. As a vendor-neutral solution, Connexall intelligently manages alarms and optimizes workflows to improve staff experience and patient safety. To learn more, visit
Business Wire
33 minutes ago
- Business Wire
Hinge Health to announce second quarter 2025 financial results on August 5, 2025
SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) announced today that it will report its financial results for the quarterly period ended June 30, 2025, after the close of the market on Tuesday, August 5, 2025. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relations website at A replay of the webcast will be available on the same website shortly after its completion. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, starting with musculoskeletal conditions. Leveraging an AI-powered care model, a wearable device, and access to expert clinicians, Hinge Health delivers personalized, evidence-based care that helps people move beyond pain, improving member outcomes and experiences and reducing costs for clients. The company is headquartered in San Francisco, California.
Yahoo
an hour ago
- Yahoo
Morphic Medical obtains CE mark for obesity treatment
Morphic Medical has obtained an EU CE mark for RESET, a device designed to target the underlying cause of obesity and type 2 diabetes (T2D). The Boston-headquartered company's RESET is a novel duodenal-jejunal bypass liner (DJBL) that mimics the effect of gastric bypass surgery and is positioned as a less-invasive option for people with T2D and obesity who have not responded well to medications or require a 'bridge' ahead of bariatric surgery. Implanted endoscopically into the upper region of the small intestine and left in place for up to nine months, RESET creates a physical barrier between receptors in the intestinal wall and food. The approach has been demonstrated to improve weight reduction and metabolic conditions by enhancing natural hormones in the gut in a manner comparable to glucagon-like peptide-1 (GLP-1) agonists. A UK study conducted at the Sandwell and West Birmingham National Health Service (NHS) Trust demonstrated that RESET's use in individuals with diabetes and obesity resulted in an average weight reduction of 17.4kg at the three-year follow up after receiving the treatment, and a 1.9% reduction in blood glucose levels alongside improvements in blood pressure and cholesterol. Morphic Medical president and CEO, Joseph Virgilio commented: "This critical regulatory milestone is an important step toward delivering on our promise and accomplishing our mission to alleviate the symptoms of obesity and metabolic disorders such as T2D for patients fighting these global epidemics. 'We're excited to help patients who have failed to achieve their goals through a programme of diet, exercise, and medical management, and are looking for an alternative therapy.' RESET is currently only available for investigational use in the US. To support a regulatory filing with the US Food and Drug Administration (FDA), Morphic is currently enrolling patients in the STEP-1 RESET pivotal trial (NCT04101669). Planned for completion in 2026, STEP-1 is a multi-centre, randomised, sham-controlled trial that plans to enrol a total of 264 patients to evaluate the safety and effectiveness of RESET, as per the study's listing on "Morphic Medical obtains CE mark for obesity treatment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
